Generic medicine

Denosumab: Brands, Price & Uses in Bangladesh

Denosumab is a human monoclonal antibody (RANK ligand inhibitor) marketed under different brand names and dosing schedules depending on indication.

Forms:SC Injection

About Denosumab

Indications of Denosumab

Denosumab is a human monoclonal antibody (RANK ligand inhibitor) marketed under different brand names and dosing schedules depending on indication. Approved uses include:

Established / FDA-approved uses

  • Osteoporosis: Treatment of postmenopausal women with osteoporosis at high risk for fracture; treatment to increase bone mass in men with osteoporosis at high risk for fracture; treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture.
  • Cancer treatment-induced bone loss: To increase bone mass in patients at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer, or adjuvant aromatase inhibitor therapy for breast cancer.
  • Skeletal-related events (SRE) in cancer: Prevention of SREs (pathologic fracture, radiation to bone, spinal cord compression, or surgery to bone) in patients with multiple myeloma and in patients with bone metastases from solid tumors.
  • Giant cell tumor of bone: Treatment in adults and skeletally mature adolescents when the tumor is unresectable or surgical resection is likely to result in severe morbidity.
  • Hypercalcemia of malignancy: Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

The osteoporosis-dose formulation of Denosumab and the higher oncology-dose formulation of Denosumab are not interchangeable; the correct brand/strength depends on the indication.

Dosage & Administration of Denosumab

Osteoporosis and Cancer Treatment-Induced Bone Loss

IndicationDoseFrequency
Postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, hormone-ablation-related bone lossDenosumab 60 mg subcutaneouslyOnce every 6 months

Skeletal-Related Events in Bone Metastases / Multiple Myeloma

IndicationDoseFrequency
Prevention of SREs in bone metastases from solid tumors or multiple myelomaDenosumab 120 mg subcutaneouslyOnce every 4 weeks

Giant Cell Tumor of Bone

Denosumab 120 mg subcutaneously every 4 weeks, with additional 120 mg doses on days 8 and 15 of the first month of therapy (loading doses).

Hypercalcemia of Malignancy

Denosumab 120 mg subcutaneously every 4 weeks, with additional 120 mg doses on days 8 and 15 of the first month of therapy.

All patients receiving Denosumab should have adequate calcium and vitamin D supplementation, particularly during the first weeks of treatment. See Administration for injection technique and Precautions for pre-treatment evaluation.

Side Effects of Denosumab

Common

  • Back pain, pain in extremities, musculoskeletal pain
  • Hypercholesterolemia
  • Urinary tract infection
  • Fatigue, asthenia
  • Hypophosphatemia, nausea, diarrhea, anemia (more common with oncology-dose Denosumab)
  • Skin reactions: rash, eczema, dermatitis

Serious (see Precautions and Warnings)

  • Severe hypocalcemia
  • Serious infections (including skin infections, endocarditis)
  • Osteonecrosis of the jaw
  • Atypical femoral fractures
  • Multiple vertebral fractures after discontinuation of Denosumab

Contraindications of Denosumab

  • Hypocalcemia: Pre-existing, uncorrected hypocalcemia is an absolute contraindication to Denosumab; it must be corrected before starting therapy.
  • Hypersensitivity: Known clinically significant hypersensitivity to Denosumab or any component of the formulation.
  • Pregnancy: Denosumab is contraindicated in pregnancy due to demonstrated risk of fetal harm (see Pregnancy and Lactation).

Frequently Asked Questions about Denosumab

What is Denosumab used for?

Denosumab is used to treat osteoporosis in postmenopausal women and in men at high risk of fracture, to treat bone loss caused by certain cancer hormone therapies, and, at a higher dose and more frequent schedule, to prevent skeletal complications from bone metastases, treat giant cell tumor of bone, and manage hypercalcemia of malignancy.

How is Denosumab given?

Denosumab is given as a subcutaneous (under-the-skin) injection by a healthcare professional, into the upper arm, thigh, or abdomen. The dose and frequency of Denosumab (every 6 months for osteoporosis, or every 4 weeks for cancer-related uses) depend on why it is being prescribed.

Can Denosumab be used during pregnancy?

No. Denosumab is contraindicated in pregnancy because it can cause harm to the developing fetus. Women who can become pregnant should use effective contraception during Denosumab treatment and for at least 5 months after the last dose. If pregnancy occurs, contact your physician immediately.

What are the most serious risks of Denosumab?

Denosumab can cause severe low blood calcium (hypocalcemia), especially in people with kidney problems; rare jaw bone problems (osteonecrosis of the jaw); unusual thigh bone fractures with long-term use; and an increased risk of serious infections, since Denosumab affects part of the immune system involved in bone remodeling. Report any thigh/groin pain, jaw pain or swelling, or signs of infection to your doctor promptly.

What happens if I stop Denosumab?

Stopping Denosumab, particularly when used for osteoporosis, can lead to rapid rebound bone loss and an increased risk of multiple spinal (vertebral) fractures. Do not stop Denosumab without talking to your physician, who may recommend switching to another bone-protective medicine to prevent this rebound effect.

Do I need calcium and vitamin D while on Denosumab?

Yes. All patients taking Denosumab should take calcium and vitamin D supplements as directed by their physician, since Denosumab can lower blood calcium levels, and adequate supplementation helps reduce this risk.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.

DoctorBlogArticles